POSE 2.0

Datasheet Journal

Overview

The minimally invasive endoluminal approach has evolved to become a mainstream treatment option for obesity. Particularly, endoscopic remodelling of the stomach and restricting the gastric lumen by placing multiple, internal, full-thickness suture plication has been shown to affect hunger and appetite and to induce effective and sustained weight-loss.

The modified POSE procedure (POSE 2.0) aims to narrow and shorten the stomach significantly in comparison with its original size. Involving the use of the incisionless operating platform, POSE 2.0 has 4 distinct componants:

  • Transport
  • g-Lix
  • g-Prox EZ
  • g-Cath EZ

The flexible transport (18mm) has a control handle with 2 wheels that can be used to deflect the tip in all 4 directions. It has 4 working channels designed for deployment of the accessories, and an additional side port for insertion of an ultra-thin upper endoscope.

The g-Lix is a flexible tissue anchor catheter with a helical design at the distal end used for anchoring and positioning the target tissue inside the g-Prox.

The multi-functional rotatable g-Prox EZ endoscopic grasper is used for tissue grasping and mobilisation. Each distal serrated jaw is 3.3 cm in length and can capture a large amount of tissue. In the jaws, there is a suture cutting component to trim the excess g-Cath EZ suture tail.

The g-Cath EZ tissue anchor delivery catheter is introduced through the lumen at the proximal end of the g-Prox EZ. It is preloaded with a dynamic snow shoe suture anchor and has a needle at the distal end. Once the target tissue is mobilised inside g-Prox, the needle penetrates through the tissue and releases the pair of preloaded suture anchors and cinches them to form a plication

Product Video

Product Variations

Product Code Description
500100 Transport-R (Right Angle)
208220 G-Prox EZ 33
301010 g-Lix
208100 g-Cath EZ Delivery Catheter
POSE-KIT Pose 2.0 Kit (includes Transport-R (Right Angle), G-Prox EZ 33, g-Lix, g-Cath EZ Delivery Catheter)

POSE 2.0

Obesity is on the rise
Obesity rates are increasing globally at an alarming rate
1) Hales C, et al. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018. NCHS Data Brief, 360, February 2020.
2) World Health Organization, Obesity and Overweight Fact Sheet, 1 April 2020.
3) Hanna Ritchie and Max Roser (2017) Obesity, Published online at OurWorldInData.org, Retrieved from: https://ourworldindata.org/obesity.

Obesity is associated with many serious diseases

  • Obesity (BMI >30) is one of the biggest drivers of preventable chronic diseases and health care cost in the United States, ranging from $147B to $210B per year (1)
  • Obesity costs the global economy $2 trillion annually or 2.8% of global GDP (2)
  • Healthcare costs for individuals with severe obesity are 81% higher than normal BMI adults (3)
  • Obesity is associated with a 50 – 100% increased risk of premature death (4)
  • Early evidence indicates that obesity is a major risk factor among patients with COVID-19 (5)
Diseases associated with Obesity
1) Cawley J and Meyerhoefer C. The Medical Care Costs of Obesity: An Instrumental Variables Approach. Journal of Health Economics, 31(1): 219-230, 2012; And Finkelstein, Trogdon, Cohen, et al. Annual Medical Spending Attributable to Obesity. Health Affairs, 2009. 2Richard Dobbs, James Manyika, The Obesity Crisis, Cairo Review of Global Affairs, July 5, 2015 https://www.mckinsey.com/mgi/overview/in-the-news/the-obesity-crisis.
3) Arterburn DE, Maciejewski ML, Tsevat J. Impact of morbid obesity on medical expenditures in adults. Int J Obes, 29(3): 334-339, 2005. 4Office of the Surgeon General – U.S. Department of Health and Human Services. Over weight and obesity: health consequences. Accessed March 2012 from http://www.surgeongeneral.gov/topics/obesity/calltoaction/fact_consequences.html.
5) Caussy, Cyrielle, et al. Prevalence of obesity amount adult inpatients with COVID-19 in France. The Lancet. Published Online May 18, 2020. https://doi.org/10.1016/ S2213-8587(20)30160-1

“Treatment Gap” exists with few available solutions

  • Treatment gap exists between low effectiveness weight loss options and high risk invasive surgical procedures
  • Large patient population, typically between BMI 30 to 40, who have no effective treatment option
  • Endobariatrics fills this treatment gap
risk vs effectiveness in treatments

By continuing to browse or by clicking “Accept All Cookies,” you agree to the storing of first and third-party cookies on your device to enhance site navigation and analyse site usage. Find out more about our cookie policy.

By continuing to browse or by clicking “Accept All Cookies,” you agree to the storing of first and third-party cookies on your device. View our Cookie Policy.

> Cookie Settings

Cookie Preference Settings

Close

Your Privacy

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your device or used to make the site work as you expect it to. The information does not usually identify you directly, but it can give you a more personalized web experience. You can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, you should know that blocking some types of cookies may impact your experience on the site and the services we are able to offer.

Always Active

Essential Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site may not work then.

Cookies Used